8 Sources of evidence considered by the committee

8 Sources of evidence considered by the committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by the Centre for Reviews and Dissemination and the Centre for Health Economics, York:

  • Hodgson R, Wade R, Biswas M et al. Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (review of TA289): A Single Technology Appraisal. CRD and CHE Technology Assessment Group, August 2015

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • Novartis Pharmaceuticals

II. Professional/expert and patient/carer groups:

  • Leukaemia CARE

  • MPN Voice

  • Association of Cancer Physicians

  • British Society for Haematology

  • Cancer Research UK

  • Royal College of Pathologists

  • Royal College of Physicians

  • Royal College of Radiologists

III. Other consultees:

  • Department of Health

  • NHS England

  • NHS Hammersmith and Fulham Clinical Commissioning Group

  • NHS South Norfolk Clinical Commissioning Group

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Institute of Cancer Research

  • National Cancer Research Institute

  • NHS Centre for Reviews & Dissemination and Centre for Health Economics – York

  • National Institute for Health Research Health Technology Assessment Programme

  • National Collaborating Centre for Cancer

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on NICE's technology appraisal guidance on ruxolitinib by attending the initial committee discussion and providing a written statement to the committee. They were also invited to comment on the ACD.

  • Professor Claire Harrison, Consultant Haematologist, nominated by the Royal College of Pathologists – clinical expert

  • Dr Tim Somervaille, Honorary Consultant in Haematology, nominated by Novartis Pharmaceuticals – clinical expert

  • Colin Clayton, nominated by MPN Voice – patient expert

  • Caroline Thomas, Patient Advocate, nominated by MPN Voice – patient expert

E. Representatives from the following company attended committee meetings. They contributed only when asked by the committee chair to clarify specific issues and comment on factual accuracy.

  • Novartis Pharmaceuticals

ISBN: 978-1-4731-1774-7

  • National Institute for Health and Care Excellence (NICE)